| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis C, Chronic | 18 | 2019 | 973 | 5.26 | Why? |
| Cryoglobulinemia | 13 | 2019 | 144 | 4.49 | Why? |
| Hepatitis C | 18 | 2019 | 1514 | 3.01 | Why? |
| Vasculitis | 9 | 2018 | 691 | 2.42 | Why? |
| Sarcoidosis | 6 | 2021 | 271 | 2.11 | Why? |
| Hepacivirus | 16 | 2019 | 1509 | 1.69 | Why? |
| Takayasu Arteritis | 6 | 2018 | 83 | 1.41 | Why? |
| Antiviral Agents | 24 | 2019 | 41703 | 1.14 | Why? |
| Antibodies, Antiphospholipid | 3 | 2020 | 519 | 1.10 | Why? |
| Liver Cirrhosis | 7 | 2018 | 1810 | 1.03 | Why? |
| Immunosuppressive Agents | 15 | 2020 | 6331 | 0.95 | Why? |
| Sustained Virologic Response | 3 | 2018 | 378 | 0.92 | Why? |
| Cryoglobulins | 2 | 2017 | 51 | 0.88 | Why? |
| Expert Testimony | 8 | 2018 | 658 | 0.85 | Why? |
| Transferrins | 1 | 2019 | 2 | 0.84 | Why? |
| Health Care Costs | 3 | 2018 | 1007 | 0.79 | Why? |
| Systemic Vasculitis | 2 | 2017 | 74 | 0.79 | Why? |
| Apolipoprotein A-I | 1 | 2020 | 148 | 0.79 | Why? |
| Still's Disease, Adult-Onset | 2 | 2018 | 100 | 0.78 | Why? |
| Behcet Syndrome | 5 | 2018 | 136 | 0.77 | Why? |
| Lymphoma, Non-Hodgkin | 2 | 2018 | 403 | 0.68 | Why? |
| Imidazoles | 3 | 2018 | 631 | 0.67 | Why? |
| Plasmapheresis | 2 | 2018 | 437 | 0.65 | Why? |
| Granuloma | 1 | 2017 | 88 | 0.64 | Why? |
| Antiphospholipid Syndrome | 3 | 2017 | 533 | 0.64 | Why? |
| Rituximab | 5 | 2018 | 1096 | 0.62 | Why? |
| Drug Hypersensitivity Syndrome | 1 | 2017 | 74 | 0.61 | Why? |
| Iron | 2 | 2019 | 619 | 0.60 | Why? |
| Anemia, Iron-Deficiency | 1 | 2018 | 210 | 0.59 | Why? |
| Sjogren's Syndrome | 5 | 2018 | 284 | 0.59 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.58 | Why? |
| Cardiotonic Agents | 1 | 2018 | 418 | 0.56 | Why? |
| Insulin Resistance | 2 | 2018 | 669 | 0.56 | Why? |
| Autoimmune Diseases | 6 | 2018 | 1996 | 0.52 | Why? |
| Rectal Neoplasms | 1 | 2018 | 278 | 0.51 | Why? |
| Pericarditis | 1 | 2019 | 417 | 0.51 | Why? |
| Disease Eradication | 2 | 2019 | 581 | 0.50 | Why? |
| France | 15 | 2020 | 12074 | 0.50 | Why? |
| Central Nervous System Diseases | 1 | 2017 | 410 | 0.47 | Why? |
| Granulomatosis with Polyangiitis | 1 | 2014 | 161 | 0.46 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.46 | Why? |
| Thrombosis | 5 | 2021 | 7504 | 0.44 | Why? |
| Adrenal Cortex Hormones | 8 | 2020 | 6537 | 0.43 | Why? |
| Hepatitis B | 3 | 2017 | 888 | 0.42 | Why? |
| Carcinoma, Hepatocellular | 2 | 2018 | 1222 | 0.42 | Why? |
| Uveitis | 3 | 2018 | 233 | 0.42 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.42 | Why? |
| Cardiovascular Diseases | 5 | 2019 | 11497 | 0.41 | Why? |
| Ribavirin | 4 | 2017 | 1182 | 0.40 | Why? |
| Polyarteritis Nodosa | 3 | 2018 | 25 | 0.38 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.38 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.37 | Why? |
| Remission Induction | 5 | 2018 | 950 | 0.36 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 0.34 | Why? |
| Metalloproteases | 1 | 2007 | 34 | 0.34 | Why? |
| Valine | 3 | 2018 | 359 | 0.33 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.32 | Why? |
| Interleukin-2 | 2 | 2018 | 443 | 0.32 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.31 | Why? |
| Disease Management | 7 | 2018 | 6841 | 0.30 | Why? |
| Virus Activation | 1 | 2010 | 480 | 0.30 | Why? |
| Glucocorticoids | 5 | 2021 | 4431 | 0.30 | Why? |
| Humans | 100 | 2021 | 930598 | 0.30 | Why? |
| Antirheumatic Agents | 6 | 2021 | 3023 | 0.30 | Why? |
| Carbamates | 3 | 2018 | 485 | 0.29 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.29 | Why? |
| Polyneuropathies | 1 | 2007 | 157 | 0.29 | Why? |
| Rheumatic Diseases | 2 | 2021 | 2675 | 0.29 | Why? |
| Immunologic Factors | 3 | 2018 | 4206 | 0.29 | Why? |
| Pyrrolidines | 3 | 2018 | 558 | 0.28 | Why? |
| Infliximab | 3 | 2018 | 502 | 0.28 | Why? |
| Interferon-alpha | 3 | 2009 | 1442 | 0.28 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.28 | Why? |
| Receptors, Complement 3d | 3 | 2019 | 60 | 0.27 | Why? |
| Immune Tolerance | 3 | 2018 | 608 | 0.27 | Why? |
| Autoantibodies | 4 | 2019 | 2094 | 0.26 | Why? |
| Middle Aged | 53 | 2021 | 270681 | 0.26 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.25 | Why? |
| Drug Therapy, Combination | 7 | 2018 | 7268 | 0.25 | Why? |
| Hepatitis B virus | 1 | 2010 | 882 | 0.25 | Why? |
| Treatment Outcome | 20 | 2018 | 51732 | 0.25 | Why? |
| B-Lymphocytes | 4 | 2019 | 4418 | 0.25 | Why? |
| Lupus Erythematosus, Systemic | 4 | 2017 | 1380 | 0.24 | Why? |
| Female | 57 | 2021 | 380317 | 0.23 | Why? |
| Retrospective Studies | 26 | 2021 | 105322 | 0.23 | Why? |
| Genes, Immunoglobulin | 1 | 2001 | 50 | 0.23 | Why? |
| Recurrence | 4 | 2019 | 3675 | 0.22 | Why? |
| Abiraterone Acetate | 1 | 2020 | 12 | 0.22 | Why? |
| Cyclophosphamide | 3 | 2017 | 387 | 0.22 | Why? |
| Myocarditis | 1 | 2017 | 2731 | 0.22 | Why? |
| Gene Dosage | 1 | 2001 | 101 | 0.22 | Why? |
| Chemokines | 1 | 2007 | 1095 | 0.21 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2021 | 6166 | 0.21 | Why? |
| Contraindications, Drug | 2 | 2020 | 281 | 0.20 | Why? |
| Biopsy, Needle | 2 | 2018 | 303 | 0.20 | Why? |
| Hepatitis C Antibodies | 2 | 2017 | 120 | 0.20 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.20 | Why? |
| Immunoglobulin Variable Region | 1 | 2001 | 253 | 0.20 | Why? |
| Immunoglobulin Heavy Chains | 1 | 2001 | 222 | 0.20 | Why? |
| Practice Guidelines as Topic | 7 | 2020 | 15421 | 0.20 | Why? |
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 136 | 0.20 | Why? |
| Rheumatoid Factor | 1 | 2019 | 67 | 0.20 | Why? |
| Anti-Glomerular Basement Membrane Disease | 1 | 2019 | 31 | 0.20 | Why? |
| Toll-Like Receptor 9 | 1 | 2019 | 72 | 0.19 | Why? |
| Male | 53 | 2021 | 367725 | 0.19 | Why? |
| Salivary Gland Diseases | 1 | 2018 | 17 | 0.19 | Why? |
| Choristoma | 1 | 2018 | 16 | 0.19 | Why? |
| Anticoagulants | 2 | 2017 | 9563 | 0.19 | Why? |
| Aminoisobutyric Acids | 1 | 2018 | 31 | 0.18 | Why? |
| Arthralgia | 2 | 2017 | 173 | 0.18 | Why? |
| Antineoplastic Agents, Hormonal | 1 | 2020 | 203 | 0.18 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.18 | Why? |
| Polychondritis, Relapsing | 1 | 2018 | 20 | 0.18 | Why? |
| 2-Naphthylamine | 1 | 2018 | 54 | 0.18 | Why? |
| Adult | 42 | 2021 | 244371 | 0.18 | Why? |
| Nootropic Agents | 1 | 2018 | 23 | 0.18 | Why? |
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 78 | 0.18 | Why? |
| Follow-Up Studies | 10 | 2018 | 17020 | 0.18 | Why? |
| Drug Administration Routes | 1 | 2018 | 106 | 0.18 | Why? |
| Optic Nerve Diseases | 1 | 2018 | 40 | 0.18 | Why? |
| Macrocyclic Compounds | 1 | 2018 | 78 | 0.17 | Why? |
| Receptors, CXCR5 | 1 | 2017 | 35 | 0.17 | Why? |
| Aortitis | 1 | 2017 | 39 | 0.17 | Why? |
| Hepcidins | 1 | 2018 | 97 | 0.17 | Why? |
| Sclera | 1 | 2017 | 31 | 0.17 | Why? |
| Uracil | 1 | 2018 | 101 | 0.17 | Why? |
| Lactams, Macrocyclic | 1 | 2018 | 130 | 0.17 | Why? |
| Risk Factors | 13 | 2021 | 71621 | 0.17 | Why? |
| Scleritis | 1 | 2017 | 25 | 0.17 | Why? |
| Adalimumab | 2 | 2018 | 389 | 0.17 | Why? |
| Survival Analysis | 4 | 2018 | 7592 | 0.17 | Why? |
| Anilides | 1 | 2018 | 105 | 0.17 | Why? |
| Hepatitis Viruses | 1 | 2017 | 38 | 0.17 | Why? |
| Myocytes, Smooth Muscle | 1 | 2018 | 127 | 0.17 | Why? |
| Quinoxalines | 1 | 2018 | 95 | 0.17 | Why? |
| Leucine | 1 | 2018 | 121 | 0.17 | Why? |
| Tumor Necrosis Factor-alpha | 5 | 2018 | 2483 | 0.17 | Why? |
| Simeprevir | 1 | 2017 | 62 | 0.17 | Why? |
| Prevalence | 5 | 2021 | 25773 | 0.16 | Why? |
| Benzofurans | 1 | 2018 | 91 | 0.16 | Why? |
| Lymphoproliferative Disorders | 1 | 2018 | 110 | 0.16 | Why? |
| Androgen Antagonists | 1 | 2020 | 404 | 0.16 | Why? |
| Cerebral Revascularization | 1 | 1996 | 45 | 0.16 | Why? |
| Hereditary Autoinflammatory Diseases | 1 | 2017 | 72 | 0.16 | Why? |
| Endothelin-1 | 1 | 1996 | 69 | 0.16 | Why? |
| Prognosis | 10 | 2021 | 32490 | 0.16 | Why? |
| Health Planning Guidelines | 1 | 2017 | 133 | 0.16 | Why? |
| Metabolic Networks and Pathways | 1 | 2018 | 285 | 0.16 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.16 | Why? |
| Th1 Cells | 2 | 2019 | 1228 | 0.15 | Why? |
| Sex Distribution | 3 | 2018 | 2083 | 0.15 | Why? |
| Aged | 31 | 2021 | 215776 | 0.15 | Why? |
| Adipose Tissue | 1 | 2021 | 612 | 0.15 | Why? |
| Endarterectomy, Carotid | 1 | 1996 | 78 | 0.15 | Why? |
| Oxidative Stress | 1 | 2007 | 2050 | 0.15 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.15 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.15 | Why? |
| Proline | 1 | 2018 | 345 | 0.15 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.15 | Why? |
| Germinal Center | 1 | 2018 | 332 | 0.15 | Why? |
| Liver Failure | 1 | 2018 | 266 | 0.14 | Why? |
| Th17 Cells | 2 | 2018 | 657 | 0.14 | Why? |
| Ustekinumab | 1 | 2017 | 216 | 0.14 | Why? |
| B-Lymphocyte Subsets | 1 | 2017 | 372 | 0.14 | Why? |
| Neuroprotective Agents | 1 | 2018 | 240 | 0.14 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.14 | Why? |
| Benzimidazoles | 1 | 2018 | 275 | 0.14 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.14 | Why? |
| Biomarkers | 6 | 2020 | 23361 | 0.14 | Why? |
| Connective Tissue Diseases | 1 | 2017 | 187 | 0.14 | Why? |
| Infertility, Female | 1 | 2017 | 150 | 0.14 | Why? |
| Interleukins | 2 | 2018 | 762 | 0.14 | Why? |
| Healthy Volunteers | 2 | 2018 | 1444 | 0.14 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.14 | Why? |
| Biological Products | 3 | 2018 | 2331 | 0.14 | Why? |
| Publications | 1 | 2019 | 463 | 0.13 | Why? |
| Cardiomyopathy, Dilated | 1 | 2017 | 251 | 0.13 | Why? |
| Myositis | 1 | 2017 | 185 | 0.13 | Why? |
| HIV Infections | 4 | 2017 | 11620 | 0.13 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2018 | 782 | 0.13 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.13 | Why? |
| Age Distribution | 3 | 2018 | 3567 | 0.13 | Why? |
| Musculoskeletal Diseases | 1 | 2021 | 646 | 0.13 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.13 | Why? |
| Patient Transfer | 1 | 2020 | 898 | 0.13 | Why? |
| Fertilization in Vitro | 1 | 2017 | 330 | 0.13 | Why? |
| Immunohistochemistry | 2 | 2018 | 2275 | 0.13 | Why? |
| Depression | 1 | 2018 | 14116 | 0.13 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.13 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.12 | Why? |
| Blood Glucose | 2 | 2018 | 3642 | 0.12 | Why? |
| Cerebrovascular Circulation | 1 | 1996 | 340 | 0.12 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 645 | 0.12 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.12 | Why? |
| Vascular Diseases | 2 | 2018 | 846 | 0.11 | Why? |
| Severity of Illness Index | 9 | 2021 | 48226 | 0.11 | Why? |
| Paris | 3 | 2021 | 1287 | 0.11 | Why? |
| Immunoglobulins | 1 | 2017 | 811 | 0.11 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.11 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 94 | 0.11 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.11 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.11 | Why? |
| Time Factors | 7 | 2018 | 31397 | 0.11 | Why? |
| Phenotype | 3 | 2017 | 4037 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Ferritins | 1 | 2019 | 2055 | 0.10 | Why? |
| Rheumatology | 1 | 2021 | 1213 | 0.10 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1573 | 0.10 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.10 | Why? |
| Liver | 3 | 2018 | 4007 | 0.10 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.10 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.10 | Why? |
| Myocardium | 1 | 2021 | 2323 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.09 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.09 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 1165 | 0.09 | Why? |
| Incidence | 8 | 2018 | 25622 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Exanthema | 1 | 2018 | 1097 | 0.09 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.09 | Why? |
| HSP72 Heat-Shock Proteins | 1 | 2007 | 4 | 0.09 | Why? |
| Peroneal Nerve | 1 | 2007 | 13 | 0.09 | Why? |
| Metallothionein | 1 | 2007 | 20 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.09 | Why? |
| Glomerulonephritis | 1 | 2010 | 226 | 0.08 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.08 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.08 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.08 | Why? |
| Polyethylene Glycols | 2 | 2009 | 574 | 0.08 | Why? |
| Immunologic Memory | 1 | 2019 | 3362 | 0.08 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2007 | 87 | 0.08 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.08 | Why? |
| Biopsy | 3 | 2018 | 2811 | 0.08 | Why? |
| Immunoglobulin M | 4 | 2019 | 9091 | 0.08 | Why? |
| HSP90 Heat-Shock Proteins | 1 | 2007 | 98 | 0.08 | Why? |
| Eye Diseases | 1 | 2018 | 1150 | 0.08 | Why? |
| Amides | 1 | 2018 | 1864 | 0.08 | Why? |
| Young Adult | 10 | 2018 | 93724 | 0.08 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.08 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.08 | Why? |
| Kidney Failure, Chronic | 3 | 2019 | 3222 | 0.07 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.07 | Why? |
| Iodine | 1 | 1987 | 116 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.06 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Ritonavir | 1 | 2018 | 4212 | 0.06 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Weight Loss | 1 | 2008 | 826 | 0.06 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.06 | Why? |
| United States | 2 | 2020 | 46150 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Case-Control Studies | 5 | 2018 | 17671 | 0.06 | Why? |
| Neoplasms, Hormone-Dependent | 1 | 2020 | 25 | 0.06 | Why? |
| Recombinant Proteins | 2 | 2009 | 3786 | 0.06 | Why? |
| Autoimmunity | 2 | 2019 | 841 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.05 | Why? |
| Europe | 1 | 2018 | 12702 | 0.05 | Why? |
| Lip | 1 | 2020 | 61 | 0.05 | Why? |
| Tissue Plasminogen Activator | 1 | 2007 | 778 | 0.05 | Why? |
| Organ Size | 1 | 2021 | 384 | 0.05 | Why? |
| Contrast Media | 1 | 1987 | 1011 | 0.05 | Why? |
| Activated Protein C Resistance | 1 | 1999 | 7 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.05 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2019 | 58 | 0.05 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2020 | 109 | 0.05 | Why? |
| Genetic Markers | 1 | 2001 | 318 | 0.05 | Why? |
| Salivary Glands, Minor | 1 | 2018 | 16 | 0.05 | Why? |
| Peripheral Nervous System Diseases | 1 | 2001 | 193 | 0.05 | Why? |
| Flow Cytometry | 2 | 2018 | 2393 | 0.05 | Why? |
| Up-Regulation | 1 | 2007 | 2249 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Budd-Chiari Syndrome | 1 | 2018 | 31 | 0.05 | Why? |
| Adenocarcinoma | 2 | 2020 | 651 | 0.04 | Why? |
| Tumor Necrosis Factors | 1 | 2017 | 28 | 0.04 | Why? |
| Androgens | 1 | 2020 | 267 | 0.04 | Why? |
| Aortic Rupture | 1 | 2018 | 64 | 0.04 | Why? |
| Vena Cava, Inferior | 1 | 2018 | 103 | 0.04 | Why? |
| Hepatitis, Chronic | 1 | 1997 | 53 | 0.04 | Why? |
| Immunoprecipitation | 1 | 2018 | 300 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Polytetrafluoroethylene | 1 | 1996 | 19 | 0.04 | Why? |
| Portal Vein | 1 | 1999 | 193 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Constriction | 1 | 1996 | 44 | 0.04 | Why? |
| Visual Fields | 1 | 2018 | 123 | 0.04 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 393 | 0.04 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2017 | 99 | 0.04 | Why? |
| Pregnancy Rate | 1 | 2017 | 134 | 0.04 | Why? |
| Carotid Artery, Common | 1 | 1996 | 49 | 0.04 | Why? |
| Mesenteric Ischemia | 1 | 2018 | 128 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2017 | 21571 | 0.04 | Why? |
| Intraoperative Period | 1 | 1996 | 97 | 0.04 | Why? |
| Self Medication | 1 | 2017 | 131 | 0.04 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.04 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.04 | Why? |
| Oral Ulcer | 1 | 2017 | 70 | 0.04 | Why? |
| Jugular Veins | 1 | 1996 | 52 | 0.04 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.04 | Why? |
| Glomerulonephritis, IGA | 1 | 2017 | 115 | 0.04 | Why? |
| Cognition Disorders | 1 | 2001 | 574 | 0.04 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
| Carotid Artery, Internal | 1 | 1996 | 97 | 0.04 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2018 | 424 | 0.04 | Why? |
| Gene Expression Profiling | 1 | 2007 | 3788 | 0.04 | Why? |
| Aorta | 1 | 2018 | 355 | 0.04 | Why? |
| Blood Vessel Prosthesis | 1 | 1996 | 115 | 0.04 | Why? |
| Lymphoma, B-Cell | 1 | 2017 | 166 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Aorta, Thoracic | 1 | 2017 | 271 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Phosphorylation | 1 | 2018 | 1060 | 0.03 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.03 | Why? |
| Registries | 3 | 2021 | 12327 | 0.03 | Why? |
| Vision Disorders | 1 | 2018 | 260 | 0.03 | Why? |
| Cigarette Smoking | 1 | 2018 | 337 | 0.03 | Why? |
| Pulmonary Edema | 1 | 2018 | 430 | 0.03 | Why? |
| Aortic Diseases | 1 | 2018 | 362 | 0.03 | Why? |
| Immunocompromised Host | 1 | 2010 | 5150 | 0.03 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2020 | 1289 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| Biological Therapy | 1 | 2018 | 456 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| Phosphatidylethanolamines | 1 | 1992 | 57 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Prostatic Neoplasms | 2 | 2020 | 1637 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Adolescent | 6 | 2018 | 86841 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 7868 | 0.03 | Why? |
| Signal Transduction | 2 | 2019 | 7207 | 0.03 | Why? |
| Visual Acuity | 1 | 2018 | 790 | 0.03 | Why? |
| Heart | 1 | 2021 | 1791 | 0.03 | Why? |
| Pulmonary Artery | 1 | 2018 | 803 | 0.03 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.03 | Why? |
| Kidney Diseases | 1 | 2002 | 1434 | 0.03 | Why? |
| Genotype | 2 | 2001 | 4697 | 0.03 | Why? |
| Heart Diseases | 2 | 2018 | 3503 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2018 | 7972 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Animals | 2 | 2017 | 78931 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Switzerland | 1 | 2018 | 2738 | 0.03 | Why? |
| Colchicine | 1 | 2017 | 730 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.02 | Why? |
| Africa, Northern | 1 | 2010 | 539 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.02 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.02 | Why? |
| Hemolytic-Uremic Syndrome | 1 | 1987 | 22 | 0.02 | Why? |
| Polyradiculoneuropathy | 1 | 1986 | 32 | 0.02 | Why? |
| Single-Cell Analysis | 1 | 2017 | 2450 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.02 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.02 | Why? |
| Acute Kidney Injury | 1 | 1987 | 5762 | 0.02 | Why? |
| Viral Load | 2 | 2017 | 15850 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Syndrome | 1 | 2011 | 1310 | 0.02 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Infant, Newborn | 2 | 2017 | 23105 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Renal Dialysis | 2 | 2017 | 4358 | 0.02 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Venous Thrombosis | 1 | 1999 | 2739 | 0.02 | Why? |
| Child | 3 | 2017 | 70012 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Bone Neoplasms | 1 | 1987 | 287 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| Kidney Transplantation | 1 | 2002 | 5397 | 0.01 | Why? |
| Gastrointestinal Diseases | 1 | 2017 | 2580 | 0.01 | Why? |
| Motor Neurons | 1 | 2001 | 52 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Mitochondria | 1 | 2008 | 857 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2017 | 43792 | 0.01 | Why? |
| Thromboembolism | 1 | 1992 | 2101 | 0.01 | Why? |
| Lung Diseases | 1 | 1992 | 2361 | 0.01 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.01 | Why? |
| Neurologic Examination | 1 | 2001 | 428 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Body Mass Index | 1 | 2008 | 4306 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Italy | 1 | 2017 | 38444 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Kidney | 1 | 1987 | 3648 | 0.01 | Why? |
| Alanine Transaminase | 1 | 1997 | 1329 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Lupus Coagulation Inhibitor | 1 | 1992 | 262 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2002 | 9893 | 0.01 | Why? |
| Age Factors | 1 | 2008 | 21039 | 0.00 | Why? |
| Immunoglobulin A | 1 | 1997 | 3567 | 0.00 | Why? |
| Brain | 1 | 2001 | 5133 | 0.00 | Why? |